FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
FEMASYS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.63−0.02 (-1.21%)
Close on Oct 19, 2026
- Market cap
- $5.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
62.0%−8.5 pts over 5 years
Operating margin
-767.0%−99.0 pts over 5 years
Net margin
-812.3%−146.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +40.8% | +23.9% | +17.2% | – | |
| Gross profit | +31.1% | +23.0% | +14.2% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 14.2% | -455.8% | |
| Return on assets | – | – | -112.3% | |
| Current ratio | – | 1.34 | 4.53 | |
| Debt to equity | – | -0.00 | – | |
| Net debt to EBITDA | – | 0.50× | – | |
| Interest coverage | – | -552.3× | -9.3× | |
| Inventory turnover | – | – | 0.2× | |
| Capex to revenue | – | 0.8% | 22.9% | |
| Diluted shares | – | 0M | 2M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Femasys generated $68.08M from operations and spent $2.44M on capital expenditure, dividends and share buybacks. 88% of that went back into the business.
Generated
$68.08M
Used
$2.44M
Capital expenditure$2.14M88%Dividends$00%Share buybacks$290.71K12%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-812.3%
×Asset turnover0.14×
×Equity multiplier4.06×
=Return on equity, FY2025-455.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -812.3% | 0.14× | 4.06× | -455.8% |
| FY2024 | -1155.0% | 0.08× | 1.95× | -182.2% |
| FY2023 | -1329.1% | 0.05× | 1.33× | -84.8% |
| FY2022 | -944.6% | 0.05× | 1.09× | -54.8% |
| FY2021 | -639.0% | 0.07× | -1.42× | 59.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$18.63M
- Cash generatingOperating cash flow above zero-$18.69M
- Return on assets improvedROA up on the prior year-67.8% → -149.7%
- Earnings backed by cashOperating cash flow above net income-$18.69M vs -$18.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.93 → 4.53
- No dilutionShare count did not rise1M → 2M
- Gross margin improvedGross margin up on the prior year66.55% → 61.96%
- More efficientAsset turnover rose0.06 → 0.18